Our findings revealed a key role of tRiMetF31, a novel component of the miR-34a tumor suppressor network, in suppressing proliferation and angiogenesis of neuroblastoma cells, supporting the application of target molecules miR-34a, tRiMetF31, and PFKFB3 in therapeutic intervention for neuroblastoma. Here, PFKFB3 is linked to neuroblastoma.